Sociedad Americana de Hirudoterapia

Marine leech anticoagulant diversity and evolution

Comparative transcriptomics published in Journal of Parasitology (2018)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalTessler M et al. · The Journal of parasitology, 2018

Abstract

Leeches (Annelida: Hirudinea) possess powerful salivary anticoagulants and, accordingly, are frequently employed in modern, authoritative medicine. Members of the almost exclusively marine family Piscicolidae account for 20% of leech species diversity, and they feed on host groups (e.g., sharks) not encountered by their freshwater and terrestrial counterparts. Moreover, some species of Ozobranchidae feed on endangered marine turtles and have been implicated as potential vectors for the tumor-associated turtle herpesvirus. In spite of their ecological importance and unique host associations, there is a distinct paucity of data regarding the salivary transcriptomes of either of these families. Using next-generation sequencing, we profiled transcribed, putative anticoagulants and other salivary bioactive compounds that have previously been linked to blood feeding from 7 piscicolid species (3 elasmobranch feeders; 4 non-cartilaginous fish feeders) and 1 ozobranchid species (2 samples). In total, 149 putative anticoagulants and bioactive loci were discovered in varying constellations throughout the different samples. The putative anticoagulants showed a broad spectrum of described antagonistic pathways, such as inhibition of factor Xa and platelet aggregation, which likely have similar bioactive roles in marine fish and turtles. A transcript with homology to ohanin, originally isolated from king cobras, was found in Cystobranchus vividus but is otherwise unknown from leeches. Estimation of selection pressures for the putative anticoagulants recovered evidence for both positive and purifying selection along several isolated branches in the gene trees, and positive selection was also estimated for a few select codons in a variety of marine species. Similarly, phylogenetic analyses of the amino acid sequences for several anticoagulants indicated divergent evolution.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnticoagulantsBiodiversityBiological EvolutionDNA, ComplementaryFishesHigh-Throughput Nucleotide SequencingHost-Parasite InteractionsLeechesOpen Reading FramesPhylogenySalivary Glands

Resumen

Transcriptomic survey across 14 marine and freshwater leech species mapping anticoagulant gene family diversity. Identifies hirudin-like, antistasin-like, and Kazal-type expansion patterns.

Por qué esto importa para la hirudoterapia

Este estudio utilizó secuenciación de próxima generación para perfilar los transcriptomas salivales de sanguijuelas marinas de las familias *Piscicolidae* y *Ozobranchidae*, identificando 149 posibles anticoagulantes y loci bioactivos. Estos compuestos se dirigen a diversas vías hemostáticas, como la inhibición del factor Xa y de la agregación plaquetaria, ampliando la biblioteca conocida de moléculas bioactivas derivadas de sanguijuelas. Para la ASH, esta investigación evolutiva y transcriptómica resalta el vasto potencial farmacológico sin explotar de diversas especies de sanguijuelas más allá de la hirudoterapia tradicional. Sin embargo, las sanguijuelas marinas estudiadas se alimentan de peces y tortugas y no se utilizan en la práctica clínica. Además, los anticoagulantes identificados son transcripciones genéticas putativas que requieren validación funcional.

Citación

Marine leech anticoagulant diversity and evolution.

Tessler M et al. · The Journal of parasitology, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.